RxSight Heads Into Third Quarter With Wall Street Bracing For Shrinking Sales And Wider Losses

RxSight enters its third-quarter report with Wall Street expecting the wrong kind of turn. After posting $33.7 million in revenue last quarter, the maker of the Light Adjustable Lens system is forecast to bring in about $27.5 million when it reports after the close on November 3. That would be a sequential drop of roughly 18% and a 9.4% decline from the $30.3 million it generated a year earlier. For a commercial-stage medical device company whose story depends on expanding adoption, outright contraction is a meaningful shift, and the report needs to explain whether it reflects a temporary air pocket or something more lasting.

The profit picture is expected to deteriorate faster than the top line. Consensus calls for a loss of 42 cents per share, compared with a 29-cent loss last quarter and a 24-cent loss in the same period last year. That gap tells its own story. A roughly $6 million sequential revenue decline is projected to widen the per-share loss by 13 cents, which implies the Street does not expect spending to come down in step with sales. In other words, analysts see negative operating leverage, where a cost base built for growth meets a softer revenue run rate. Any evidence that management is adjusting expenses to match the new reality would be a welcome surprise; a loss that widens even beyond the 42-cent estimate would raise harder questions about the path to profitability and the company's cash needs.

Because RxSight sells both the adjustable lenses and the Light Delivery Devices used to fine-tune vision after cataract surgery, the composition of any revenue miss or beat matters as much as the headline figure. Weakness concentrated in device sales could suggest surgeons are pausing on new capital purchases while still using the systems they already own, a less damaging outcome. Softness in lens volume would be more concerning, because it speaks directly to how actively the installed base is being used and whether the procedure is gaining or losing traction in practice. Without fresh guidance on the table, the release and the accompanying commentary will carry extra weight in resetting how investors think about the rest of the year and beyond.

The market has already rendered a harsh preliminary verdict. Shares have fallen 17.8% since the last report, while the S&P 500 was essentially flat, leaving the stock more than 17 percentage points behind the broader market. At $4.93, it trades well below its 200-day moving average of $6.50 and sits much closer to the $4.40 low of its post-earnings range than to the $7.44 high. That range is also wider than the prior quarter's, a sign of rising volatility and diminished conviction. Sentiment remains bearish, though modestly less so than heading into the previous report, suggesting some of the pessimism may already be reflected in the price.

That combination creates a setup where the bar is low but the stakes are high. A result merely in line with the reduced forecasts could steady a beaten-down stock, while a clear sign that utilization is holding up could shift the narrative meaningfully. The central question is whether the expected revenue decline represents a pause in adoption that RxSight can manage through cost discipline, or the beginning of a slower growth chapter that the current expense structure was never designed to support. How management answers that will likely determine whether the recent selloff looks overdone or justified.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.